Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $49.00

Maze Therapeutics (NASDAQ:MAZE) had its price objective upped by analysts at Wedbush from $48.00 to $49.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush‘s price objective would indicate a potential upside of 39.88% from the company’s previous close.

A number of other analysts have also recently weighed in on MAZE. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. BTIG Research restated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Citigroup began coverage on shares of Maze Therapeutics in a report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Finally, Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $64.55.

Maze Therapeutics Stock Up 0.3%

Shares of MAZE traded up $0.12 during midday trading on Tuesday, reaching $35.03. The stock had a trading volume of 16,521 shares, compared to its average volume of 669,144. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -13.92 and a beta of 2.04. The company’s fifty day simple moving average is $27.94 and its two-hundred day simple moving average is $31.72. Maze Therapeutics has a 1-year low of $21.95 and a 1-year high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.01). Equities research analysts expect that Maze Therapeutics will post -2.70 earnings per share for the current year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $52,332.12. Following the transaction, the insider owned 7,007 shares of the company’s stock, valued at $182,252.07. This represents a 22.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 16,141 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $26.93, for a total value of $434,677.13. Following the completion of the sale, the chief marketing officer directly owned 16,141 shares in the company, valued at approximately $434,677.13. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 192,991 shares of company stock worth $5,187,559 in the last 90 days. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sterling Capital Management LLC increased its position in shares of Maze Therapeutics by 390.5% during the third quarter. Sterling Capital Management LLC now owns 1,089 shares of the company’s stock worth $30,000 after acquiring an additional 867 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at about $48,000. Royal Bank of Canada grew its position in shares of Maze Therapeutics by 214.1% during the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after buying an additional 1,383 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at about $80,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Maze Therapeutics during the third quarter worth about $77,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets.

The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.

Founded in 2018, Maze is headquartered in South San Francisco, California.